Thus, our findings demonstrate that a small molecule dual inhibitor for both NQO1 and GSTP1, downstream of EGFRvIII, provides a novel strategy for GBM therapy by disrupting the redox homeostasis. Here, NQO1 is linked to glioblastoma.